biOasis Technologies Ord Shs BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

GREY:BIOAF - Post by User

biOasis Technologies Ord Shs > Midatech's Glioblastoma Drug and xB3 Synergy:

<< Previous

Bullboard Posts

Next >>

Comment by prophetoffactzon Jan 15, 2023 6:20pm

72 Views

Post# 35224514

RE:RE:RE:RE:RE:RE:Midatech's Glioblastoma Drug and xB3 Synergy:

Boomskid wrote: So, poof, by what mechanism does Midatech technology deliver drugs to the brain?

jd

Midatech uses CED. Theoretically I'm wondering if it may be able to flood a specific region of the brain with drug better than IV administration and avoid systemic toxicities compared to IV administration. Perhaps xB3, given the receptor is expressed in certain regions of the brain, could further be used with such a technology to target the area. TargetedX2.

Convection-enhanced delivery (CED) is a bulk flow-driven process. Its properties permit direct, homogeneous, targeted perfusion of CNS regions with putative therapeutics while bypassing the blood-brain barrier. Development of surrogate imaging tracers that are co-infused during drug delivery now permit accurate, noninvasive real-time tracking of convective infusate flow in nervous system tissues. The potential advantages of CED in the CNS over other currently available drug delivery techniques, including systemic delivery, intrathecal and/or intraventricular distribution, and polymer implantation, have led to its application in research studies and clinical trials. The authors review the biophysical principles of convective flow and the technology, properties, and clinical applications of convective delivery in the CNS.

<< Previous

Bullboard Posts

Next >>

Gold Flora's Gramlin holds court in California cannabis market